Literature DB >> 29436917

Improved procedural safety following protocol changes for selective ophthalmic arterial infusion of chemotherapy for treatment of ocular retinoblastoma.

Simon Ammanuel1, Matthew D Alexander2, Bertil Damato3, Daniel L Cooke1, Van V Halbach1, Matthew R Amans1, Christopher F Dowd1, Randall T Higashida1, Steven W Hetts1.   

Abstract

Purpose The aim was to evaluate the impact of protocol changes in selective ophthalmic arterial infusion (SOAI) for treatment of retinoblastoma (Rb). Methods A retrospective review was completed of 35 patients with Rb who were treated with SOAI between March 2010 and January 2017. Treatment details were tabulated for each SOAI session. SOAI protocol was changed in June 2015, and differences before and after this change were evaluated using two-tail chi-square tests and independent sample t-tests to note any differences in technical complications, need for enucleation, and other outcome variables Results 125 SOAI sessions occurred. No technical complications occurred during the study. Two complications (1.6%) occurred in the postoperative setting. Both complications occurred prior to the change in protocol. Comparing the complication rates between the two protocols showed no significant difference (2.2% versus 0.0%; p = 0.505); 29 of 43 (67.4%) eyes had their vision preserved overall. Conclusions SOAI is an effective treatment for Rb. The refined protocol described herein was associated with fewer complications.

Entities:  

Keywords:  Interventional neurooncology; intra-arterial chemotherapy; retinoblastoma

Mesh:

Substances:

Year:  2018        PMID: 29436917      PMCID: PMC5967188          DOI: 10.1177/1591019918755088

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  15 in total

1.  The treatment of retinoblastoma by x-ray and triethylene melamine.

Authors:  A B REESE; G A HYMAN; N D TAPLEY; A W FORREST
Journal:  AMA Arch Ophthalmol       Date:  1958-11

2.  Radiation dose reduction in intra-arterial chemotherapy infusion for intraocular retinoblastoma.

Authors:  Daniel L Cooke; Charles E Stout; Warren T Kim; Steven W Hetts; Randall T Higashida; Van V Halbach; Christopher F Dowd; Robert G Gould
Journal:  J Neurointerv Surg       Date:  2014-01-02       Impact factor: 5.836

3.  Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.

Authors:  Alok A Khorana; Charles W Francis; Eva Culakova; Gary H Lyman
Journal:  Cancer       Date:  2005-12-15       Impact factor: 6.860

Review 4.  The Incidence of Trilateral Retinoblastoma: A Systematic Review and Meta-Analysis.

Authors:  Marcus C de Jong; Wijnanda A Kors; Pim de Graaf; Jonas A Castelijns; Annette C Moll; Tero Kivelä
Journal:  Am J Ophthalmol       Date:  2015-09-12       Impact factor: 5.258

5.  Selective ophthalmic artery chemosurgery (SOAC) for retinoblastoma: fluoroscopic time and radiation dose parameters. A baseline study.

Authors:  Srikanth R Boddu; David H Abramson; Brian P Marr; Jasmine H Francis; Y Pierre Gobin
Journal:  J Neurointerv Surg       Date:  2016-11-09       Impact factor: 5.836

Review 6.  Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy.

Authors:  C L Shields; E M Fulco; J D Arias; C Alarcon; M Pellegrini; P Rishi; S Kaliki; C G Bianciotto; J A Shields
Journal:  Eye (Lond)       Date:  2012-09-21       Impact factor: 3.775

7.  Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis.

Authors:  Shigenobu Suzuki; Takashi Yamane; Makoto Mohri; Akihiro Kaneko
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

8.  A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.

Authors:  David H Abramson; Ira J Dunkel; Scott E Brodie; Jonathan W Kim; Y Pierre Gobin
Journal:  Ophthalmology       Date:  2008-03-14       Impact factor: 12.079

9.  Current therapy and recent advances in the management of retinoblastoma.

Authors:  Rachna Meel; Venkatraman Radhakrishnan; Sameer Bakhshi
Journal:  Indian J Med Paediatr Oncol       Date:  2012-04

10.  Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution.

Authors:  Sheila Thampi; Steven W Hetts; Daniel L Cooke; Paul J Stewart; Elizabeth Robbins; Anuradha Banerjee; Steven G Dubois; Devron Char; Van Halbach; Katherine Matthay
Journal:  Clin Ophthalmol       Date:  2013-05-27
View more
  1 in total

Review 1.  Intra-arterial chemotherapy in retinoblastoma - A paradigm change.

Authors:  Fairooz P Manjandavida; Christina Stathopoulos; Jing Zhang; Santhosh G Honavar; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2019-06       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.